Key Takeaways:
UBS cut its price target on Ali Health Information Technology Ltd. (00241.HK) to HKD3.6 from HKD4.1, citing lower earnings visibility from the company’s increased AI and supply chain investments.
The bank maintained its Sell rating on the stock, reflecting a 12-14% reduction in its earnings forecasts for fiscal years 2027-2029, UBS said in a research report.
The revision follows Ali Health's fiscal 2026 revenue, which fell short of expectations, and a fiscal 2027 adjusted net profit guidance that was below market forecasts. While management is upgrading its strategy to focus on innovative drugs and medical AI, the associated investment costs are expected to weigh on margins, the report stated.
Increased investment and competition from key rival JD Health International Inc. (06618.HK) may further heighten earnings uncertainty for the online healthcare provider. The new HKD3.6 target implies a 12.6% downside from the stock's recent price of approximately HKD4.12.
The downgrade suggests analysts are questioning the near-term return on heavy AI investment in the online health sector. Investors will be watching for execution on the new drug-focused strategy to see if it can offset margin pressure.
This article is for informational purposes only and does not constitute investment advice.
